Bioasis Announces Allowance of Patent Application in Japan Relating to xB3 Platform Technology for the Delivery of Therapeuti...
11 September 2019 - 6:05AM
Business Wire
Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), (the
“Company” or “Bioasis”), a pre-clinical, research-stage
biopharmaceutical company developing its proprietary xB3 TM
platform technology for the delivery of therapeutics across the
blood-brain barrier (“BBB”) and the treatment of central nervous
system (“CNS”) disorders in areas of high unmet medical need,
including brain cancers and neurodegenerative diseases, today
announces that the Japanese Patent Office (Tokkyochō, JPO) issued
an Official Notice of Allowance for a Japanese patent application
covering the Company’s platform technology.
The patent application relates to Bioasis’ P97, the Company’s
core polypeptide asset for transporting therapeutic agents across
the BBB. These conjugates have the potential to treat central
nervous system disorders and brain cancers.
“We are excited about the allowance of this patent application
by the Japanese Patent Office, because this represents a
significant addition to our intellectual property protection around
our core assets in the major world markets including US, Europe and
China,” said Company Chair and Chief Executive officer Deborah
Rathjen, Ph.D. “The Bioasis business model is based on the strength
of these assets, the intellectual property that is protected by our
broad patent portfolio.”
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company
developing the xB3 platform, a proprietary technology for the
delivery of therapeutics across the BBB and the treatment of CNS
disorders in areas of high unmet medical need. The delivery of
therapeutics across the BBB represents the final frontier in
treating neurological disorders. Bioasis’ internal pipeline
programs are focused on treatments for brain cancers, including
HER2+ breast cancer brain metastases, and neurodegenerative
diseases. For more information about the Company, please visit
www.bioasis.us.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190910006089/en/
Deborah Rathjen, Ph. D., Executive Chair deborah@bioasis.us +1
203 533 7082
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Jan 2025 to Feb 2025
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Feb 2024 to Feb 2025